Download TO DOWNLOAD OUR Mobic INFORMATION PACKAGE

Parker & Waichman, LLP Attorneys at Law
Mobic Information Guide
The Case Against Mobic:
Mobic has revealed a greater risk of heart attacks in early data
than found with Merck & Co. Inc.'s now-withdrawn Vioxx, a
veteran U.S. Food and Drug Administration scientist told an FDA
advisory panel.
Manufacturer:
Boehringer Ingelheim
Generic Name:
Meloxicam
Date Approved:
April 14, 2000
Status:
On the market
Approved Uses:
Adult osteoarthritis
Serious Side Effects:
Heart Attack
Blood clots
Stroke
Related Topics:
Bextra
Celebrex
Vioxx
Cox- II Inhibitors
Blood Clots
Heart Attacks
Stroke
Defective Drugs
Diseases
The drug, made by privately-held Boehringer Ingelheim
Pharmaceuticals, exhibited the effect in a new, yet-to-be
published study, said David Graham, associate director for
science and medicine at the FDA's Office of Drug Safety.
"We found an increased risk," Graham said. "It's one study. It's
the only study." Mobic has become the top-selling prescription
pain drug since Merck pulled Vioxx, and any possible heart attack
risk is important as more patients take the drug, Graham said.
Graham, along with other scientists outside the FDA, analyzed
data culled from California's Medicaid program of more than
15,000 heart attack patients, making it the largest study to date on
such risks. They found the statistical risk of heart attack was 1.37
for Mobic, compared to 1.32 with Vioxx and 1.09 with Celebrex.
Celebrex, Bextra and Vioxx, are part of a class called Cox-2
inhibitors, a newer type of non-steroidal anti-inflammatory drug
(NSAID). Mobic is classified as a Cox-2 in some countries but is
not considered part of that group in the United States, where it’s
only classified as part of the larger NSAID class, a Boehringer
spokesman said.
Abbott Laboratories, which co-markets Mobic in the United
States, said last month it expected U.S. sales of the drug to hit $1
billion in 2005.
If you or a loved one has been injured by Mobic, Parker &
Waichman, LLP will evaluate your case for free. Click here for a
free, no obligation, case evaluation.
Mobic (Meloxicam)
From Wikipedia, the free encyclopedia.
Meloxicam is a nonsteroidal anti-inflammatory drug used to relieve the symptoms of arthritis,
primary dysmenorrhoea, pyrexia; and as an analgesic, especially where there is an
inflammatory component. It is closely related to piroxicam.In Europe it is marketed under the
names of Movalis, Melox, and Recoxa.
Mechanism of action
Meloxicam is an NSAID and, as such is a cyclooxygenase (COX) inhibitor. It is generally
marketed under the name MOBIC. Meloxicam has been shown, especially at its low
therapeutic dose, to selectivly inhibit COX-2 over COX-1.
Adverse effects
Meloxicam use can result in gastrointestinal toxicity, tinnitus, headache, and rash. The risk of
adverse side effects is lower than with piroxicam, diclofenac, or naproxen. Although it does
inhibit thromboxane A, it does not appear to do so at levels that would interfere with platelet
function.
Approval status
Meloxicam is quite popular in Europe for treatment of rheumatoid arthritis. It has recently (as
of 2004) been approved for use in treating osteoarthritis in the United States.
If you or a loved one has been injured by Mobic, Parker & Waichman, LLP will evaluate your
case for free. Click here for a free, no obligation, case evaluation.